FDAFebruary 13, 2026device

Paradigm REAL-Time Insulin Pump (MMT-522, MMT-722)

Official recall recorded by the U.S. Food & Drug Administration.

The hazard

All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.

What to do

FDA enforcement status: Ongoing

Brands named

medtronic minimedmedtronic

UPCs

00613994409423006139946226006139946227476139944077330061399440774000613994136374006139942716000061399410647600613994373120006139944094780061399431242600613994151780

Recall history

Other federal recalls tied to the same brand — a factual pattern, straight from the source data.

Own something like this?

AllClear screens your whole list against every CPSC, FDA, USDA and NHTSA recall — and tells you the day a new one names something you own.

Start free — 200 items, no card →